Human Papillomavirus (HPV) vaccine immunisation as an intervention programme for the prevention of cervical cancer and other similar HPV genotype-related diseases in South Africa:

Some Ethical and Legal Matters for Consideration

Lineo Mamphi Motopi

Student number: 333003

A research report submitted in partial fulfilment of the degree of MSc Med in the field of Bioethics and Health Law, Steve Biko Centre for Bioethics, Faculty of Health Sciences University of the Witwatersrand

Supervisor: Professor Ames Dhai

Johannesburg 28 February 2014

DECLARATION

I Lineo 'Mamphi Motopi declare that this research report *Human Papillomavirus* (*HPV*) vaccine immunisation as an intervention programme for the prevention of cervical cancer and other similar HPV genotype-related diseases in South Africa: Some Ethical and Legal Matters for Consideration submitted for assessment for the MSc Medicine (Bioethics and Health Law) is my own unaided work.

I have followed the required conventions in referencing the writing, ideas, and thoughts of others. It is being submitted for the degree of Master of Science in Medicine (Bioethics and Health Law) at the University of the Witwatersrand, Johannesburg.

This work has not been submitted for any other degree or examination at any other academic institution.

Signature

Date

ABSTRACT

A new opportunity to reduce cervical cancer deaths as well as other HPV associated diseases arises from recently developed prophylactic vaccines. A large body of scientific literature concludes that the vaccines provide 100% protection against the oncogenic (highrisk) HPV types 16 and 18, which are responsible for about 70% of all cervical cancers in women. The vaccines also protect against infections with HPV 6 and 11, the cause of about 90% of genital warts (condylomataacuminata) in both males and females. South Africa is faced with uncertainties about how to implement a HPV vaccine immunisation programme aimed at the improvement of health in relation to the burden of disease caused by cervical cancer and related HPV-implicated diseases whilst struggling to provide the most basic of healthcare services in the midst of a HIV pandemic and a diminished base of key healthcare professionals. In such a context and relative to other priorities and the comparative benefits of different interventions, should, and if so why should South Africa invest in a HPV vaccine immunisation programme; likewise, if not, why not? In this research, report I will provide the main ethical and legal issues related to the implementation of a National HPV vaccine immunisation intervention programme. The research method used is a literature review of some ethical & legal issues in HPV vaccine immunisation analysing findings by way of critical thinking and moral reasoning. The outcomes of my research report suggest that South Africa is bound ethically and legally to provide HPV vaccine immunisation as an intervention to reduce the scourge of HPV infections, especially cervical cancer-based on the outcomes, I make recommendations concerning policy changes at the National level. These changes include interventions targeting the youth with an HPV vaccine immunisation programme included as one type of intervention.

| Table of Content | page |
|--|------|
| Chapter 1 Introduction, Literature Review and Methodology 1.1 The burden of cervical cancer | 1 |
| 1.2 South African cervical cancer statistics | 4 |
| 1.3 Risk factors for cervical cancer | 6 |
| 1.4 Human Papillomaviruses (HPV) and cervical cancer | 8 |
| 1.5 HPV infection preventative strategies | 10 |
| 1.6 Vaccine development, efficacy, safety, and cross protection of other HPV genotypes | 11 |
| 1.7 Public Health considerations in HPV vaccine immunisation programmes: The challen | ges |
| 1.7.1 Basic issues in public health interventions 1.7.2 Efficacy: Can the HPV vaccine stand up to the rule that | 12 |
| vaccines are efficacious? | 13 |
| 1.7.3 Cross protection: Can the HPV vaccine offer any cross-protection? | 14 |
| 1.7.4 Safety and duration of protection: How safe is the HPV vaccine? | |
| How long does one dose last? | 15 |
| 1.7.5 Cost: Can the South African government afford the HPV vaccine immunisat | ion? |
| 1.7.6 Challenges: What are some of the other challenges? | |
| faced with when introducing the HPV vaccine immunisation? | 16 |
| 1.8 Methodology, objectives, and outcomes | 17 |
| 1.8.1 Design | 17 |
| 1.8.2 Methods | 17 |
| 1.8.3 Objectives | 18 |
| 1.8.4 Outcomes | 18 |
| 1.8.5 Limitations | 18 |

Chapter 2 Ethical Issues Concerning HPV vaccine immunisation in South Africa

| 2.1 Introduction | 20 |
|--|----|
| 2.1.1 Purpose of immunisation programmes | 20 |
| 2.1.2 General controversies in vaccine immunisation programmes | 21 |
| 2.1.3 The individual and the public | 22 |
| 2.1.4 Ethical basis of most public health vaccine immunisation programmes | 27 |
| 2.1.5 Possible dominance of Pharmaceutical industry with HPV programme | 30 |
| 2.2 Some ethical issues in HPV vaccine immunisation | 32 |
| Chapter 3 Legal Issues in HPV vaccine immunisation | |
| 3.1 Legal issues in vaccine immunisation of children in South Africa | 41 |
| 3.2 Legal issues in HPV vaccine immunisation: Female and male children | 44 |
| 3.3 Specific legislation on reproductive health of children, consent and debut | 47 |
| 3.3.1 Age of sexual consent | 48 |
| 3.3.2 Sexual debut | 53 |
| Chapter 4 Policy Recommendations and Concluding Remarks | |
| 4.1 Policy development, recommendations, delivery strategies and monitoring & evaluation | 57 |
| 4.2 Concluding remarks | 62 |
| References | 64 |

Annexure A: Human Research Ethics Committee Clearance Certificate